Integrated Quantitative Investments LLC Takes Position in Inspire Medical Systems, Inc. (NYSE:INSP)

Integrated Quantitative Investments LLC acquired a new position in shares of Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 6,800 shares of the company's stock, valued at approximately $1,261,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. First Horizon Advisors Inc. lifted its position in Inspire Medical Systems by 885.7% during the 4th quarter. First Horizon Advisors Inc. now owns 138 shares of the company's stock worth $26,000 after buying an additional 124 shares in the last quarter. Huntington National Bank raised its holdings in Inspire Medical Systems by 228.3% during the fourth quarter. Huntington National Bank now owns 174 shares of the company's stock worth $32,000 after acquiring an additional 121 shares in the last quarter. Harbour Investments Inc. grew its stake in Inspire Medical Systems by 101.0% in the fourth quarter. Harbour Investments Inc. now owns 197 shares of the company's stock valued at $37,000 after purchasing an additional 99 shares in the last quarter. AlphaQuest LLC increased its position in shares of Inspire Medical Systems by 7,275.0% during the 4th quarter. AlphaQuest LLC now owns 295 shares of the company's stock worth $55,000 after purchasing an additional 291 shares during the last quarter. Finally, Smartleaf Asset Management LLC raised its stake in shares of Inspire Medical Systems by 178.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 357 shares of the company's stock worth $66,000 after purchasing an additional 229 shares in the last quarter. Institutional investors own 94.91% of the company's stock.

Remove Ads

Insider Buying and Selling at Inspire Medical Systems

In other Inspire Medical Systems news, CTO John Rondoni sold 583 shares of the business's stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $170.49, for a total transaction of $99,395.67. Following the completion of the transaction, the chief technology officer now owns 10,424 shares of the company's stock, valued at approximately $1,777,187.76. The trade was a 5.30 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Randy Ban sold 25,584 shares of the stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $183.50, for a total transaction of $4,694,664.00. Following the completion of the transaction, the insider now directly owns 7,259 shares of the company's stock, valued at $1,332,026.50. This trade represents a 77.90 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.30% of the company's stock.

Wall Street Analysts Forecast Growth

INSP has been the subject of a number of recent analyst reports. KeyCorp reiterated an "overweight" rating and issued a $234.00 price target (down previously from $236.00) on shares of Inspire Medical Systems in a research note on Friday, January 24th. Piper Sandler cut their target price on shares of Inspire Medical Systems from $260.00 to $233.00 and set an "overweight" rating for the company in a research note on Monday, February 10th. Truist Financial lowered their price target on Inspire Medical Systems from $250.00 to $235.00 and set a "buy" rating on the stock in a research report on Tuesday, February 11th. Robert W. Baird cut their price objective on Inspire Medical Systems from $252.00 to $248.00 and set an "outperform" rating for the company in a research report on Tuesday, February 11th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $260.00 price objective on shares of Inspire Medical Systems in a research report on Tuesday, February 11th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, Inspire Medical Systems presently has an average rating of "Moderate Buy" and a consensus price target of $226.70.

Inspire Medical Systems Stock Up 0.7 %

Shares of NYSE:INSP traded up $1.05 during trading on Wednesday, reaching $142.46. 117,793 shares of the company traded hands, compared to its average volume of 590,135. The firm has a market capitalization of $4.24 billion, a PE ratio of 81.41, a PEG ratio of 2.86 and a beta of 1.39. Inspire Medical Systems, Inc. has a 52 week low of $123.00 and a 52 week high of $257.40. The company's 50 day moving average is $173.26 and its two-hundred day moving average is $186.81.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.41. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. As a group, research analysts anticipate that Inspire Medical Systems, Inc. will post 2.16 EPS for the current year.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.